Matiotti-Neto Mario, Eskander Mariam F, Tabatabaie Omidreza, Kasumova Gyulnara, Bliss Lindsay A, Ng Sing Chau, Tawa Nicholas E, Murphy Blanche, Critchlow Jonathan F, Tseng Jennifer F
Am Surg. 2017 Dec 1;83(12):1336-1342.
The superiority of surgical cut-down of the cephalic vein versus percutaneous catheterization of the subclavian vein for the insertion of totally implantable venous access devices (TIVADs) is debated. To compare the safety and efficacy of surgical cut-down versus percutaneous placement of TIVADs. This is a single-institution retrospective cohort study of oncologic patients who had TIVADs implanted by 14 surgeons. Primary outcomes were inability to place TIVAD by the primary approach and postoperative complications within 30 days. Multivariate analysis was performed by logistic regression. Secondary outcomes included operative time. Two hundred and forty-seven (55.9%) percutaneous and 195 (44.1%) cephalic cut-down patients were identified. The 30-day complication rate was 5.2 per cent: 14 patients (5.7%) in the percutaneous and nine (4.6%) in the cut-down group. The technique was not a significant predictor of having a 30-day complication (odds ratio = 0.820; 95% confidence interval 0.342-1.879). Implantation failure was observed in 16 percutaneous patients (6.5%) and 28 cut-down patients (14.4%) (adjusted odds ratio for cephalic vs cut-down = 2.387; 95% confidence interval 1.275-4.606). The median operative time for percutaneous patients was 46 minutes (interquartile range = 35, 59) versus 37.5 minutes (interquartile range = 30, 49) for cut-down patients(P < 0.0001). Both the percutaneous and cut-down technique are safe and effective for TIVAD implantation. Operative times were shorter and the odds of implantation failure higher for cephalic cut-down. As implantation failure is common, surgeons should familiarize themselves with both techniques.
对于完全植入式静脉通路装置(TIVADs)的植入,头静脉手术切开与锁骨下静脉经皮穿刺置管哪种方法更具优势存在争议。为比较TIVADs手术切开植入与经皮植入的安全性和有效性。这是一项单机构回顾性队列研究,研究对象为14位外科医生为其植入TIVADs的肿瘤患者。主要结局指标为初次入路无法植入TIVAD以及30天内的术后并发症。采用逻辑回归进行多变量分析。次要结局指标包括手术时间。共识别出247例(55.9%)经皮植入患者和195例(44.1%)头静脉切开患者。30天并发症发生率为5.2%:经皮植入组14例(5.7%),切开植入组9例(4.6%)。该技术并非30天并发症的显著预测因素(比值比=0.820;95%置信区间0.342 - 1.879)。16例经皮植入患者(6.5%)和28例切开植入患者(14.4%)出现植入失败(头静脉切开与切开植入的校正比值比=2.387;95%置信区间1.275 - 4.606)。经皮植入患者的中位手术时间为46分钟(四分位间距=35,59),而切开植入患者为37.5分钟(四分位间距=30,49)(P<0.0001)。经皮和切开技术对于TIVADs植入均安全有效。头静脉切开的手术时间更短,但植入失败几率更高。由于植入失败很常见,外科医生应熟悉这两种技术。